Clinical Trials Logo

Clinical Trial Summary

The present study will evaluate the use of osimertinib as 1st line therapy for patients with advanced EGFR positive non-small cell lung cancer who are treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.


Clinical Trial Description

This will be an observational, multicentric, retrospective/ prospective analysis of patients with advanced EGFR positive non-small cell lung cancer that receive osimertinib as 1st line therapy. The patient data will be collected at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology during scheduled patient clinical visits, from February 2020 for a total period of three years. The biological material obtained from the patients of this analysis will be possibly used in a future translational study as an exploratory analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05127382
Study type Observational
Source Hellenic Cooperative Oncology Group
Contact Maria Drizou, MD
Phone +30 2104807252
Email [email protected]
Status Recruiting
Phase
Start date February 1, 2020
Completion date January 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03866980 - A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer Phase 3
Recruiting NCT03692442 - Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
Recruiting NCT03769103 - Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC Phase 2
Completed NCT02129699 - Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy Phase 3
Recruiting NCT03866993 - A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer Phase 3
Not yet recruiting NCT04184921 - Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients